Michael H. Davidson to Clofibric Acid
This is a "connection" page, showing publications Michael H. Davidson has written about Clofibric Acid.
Connection Strength
1.875
-
A clinical puzzle: fibrates and homocysteine elevation: editorial to: "fibrates may cause an abnormal urinary betaine loss which is associated with elevations in plasma homocysteine" by M. Lever et al. Cardiovasc Drugs Ther. 2009 Oct; 23(5):341-2.
Score: 0.361
-
Safety considerations with fibrate therapy. Am J Cardiol. 2007 Mar 19; 99(6A):3C-18C.
Score: 0.297
-
Statin/fibrate combination in patients with metabolic syndrome or diabetes: evaluating the risks of pharmacokinetic drug interactions. Expert Opin Drug Saf. 2006 Jan; 5(1):145-56.
Score: 0.278
-
Pharmacokinetic interactions between statins and fibrates. Am J Cardiol. 2005 Nov 07; 96(9A):44K-49K; discussion 34K-35K.
Score: 0.274
-
Management of dyslipidemia in patients with complicated metabolic syndrome. Am J Cardiol. 2005 Aug 22; 96(4A):22E-25E.
Score: 0.271
-
Novel targets that affect high-density lipoprotein metabolism: the next frontier. Am J Cardiol. 2009 Nov 16; 104(10 Suppl):52E-7E.
Score: 0.091
-
A review of the current status of the management of mixed dyslipidemia associated with diabetes mellitus and metabolic syndrome. Am J Cardiol. 2008 Dec 22; 102(12A):19L-27L.
Score: 0.085
-
High-density lipoprotein metabolism: potential therapeutic targets. Am J Cardiol. 2007 Dec 03; 100(11 A):n32-40.
Score: 0.079
-
Targeting high-density lipoprotein cholesterol in the management of cardiovascular disease. Am Heart Hosp J. 2007; 5(4):210-6.
Score: 0.075
-
Comparative effects of lipid-lowering therapies. Prog Cardiovasc Dis. 2004 Sep-Oct; 47(2):73-104.
Score: 0.063